论文部分内容阅读
所谓免疫抑制疗法,就是试图用一系列药物抑制机体有害的免疫反应。它始于Schwartz等(1958)的6—MP动物实验。临床上,1962年Dameshek等首先报告用6—MP和硫代鸟嘌呤治疗自身免疫性溶血性贫血。此后,本疗法被广泛地采用,主要是治疗包括胶原病在内的自身免疫性疾病和移植免疫反应。但无庸讳言,由于免疫抑制剂存在的副作用,大大地限制了它的用途。至今,除部分病种外,对许多病的疗效都不是那样令人满意,不能当作首选药物来使用。作为辅佐药物,其具体使用方法亦未臻完善。不过,今天,经过十多年的临床应用,至少在胶原病这
The so-called immunosuppressive therapy, is trying to use a series of drugs to suppress the body’s harmful immune response. It started with 6-MP animal experiments by Schwartz et al. (1958). Clinically, in 1962 Dameshek et al. First reported the treatment of autoimmune hemolytic anemia with 6-MP and thioguanine. Since then, the therapy is widely used, mainly to treat autoimmune diseases including collagen disease and transplant immune response. However, it goes without saying that the use of immunosuppressive agents greatly limits their usefulness due to their side effects. So far, except for some diseases, the efficacy of many diseases is not so satisfactory, can not be used as the preferred drug. As adjuvant drugs, its specific methods of use are not perfect. However, today, after more than a decade of clinical application, at least in collagen disease